A pharmaceutical composition is described. The composition comprises:(i) a drug component comprising at least one beclomethasone compound selected from beclomethasone and the pharmaceutically acceptable derivatives thereof and at least one long acting beta-2-agonist; (ii) a propellant component comprising 1,1- difluoroethane (HFA-152a); and (iii) glycerol.